Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
J Neuroimmunol
; 345: 577282, 2020 08 15.
Article
in English
| MEDLINE | ID: covidwho-437267
ABSTRACT
A multiple sclerosis patient infected by SARS-CoV-2 during fingolimod therapy was hospitalized with moderate clinical features, and recovered in 15 days. High levels of CCL5 and CCL10 chemokines and of antibody-secreting B cells were detected, while the levels other B- and T-cell subsets were comparable to that of appropriate controls. However, CD4+ and CD8+ cells were oligoclonally expanded and prone to apoptosis when stimulated in vitro. This study suggests that fingolimod-immunosuppressed patients, despite the low circulating lymphocytes, may rapidly expand antibody-secreting cells and mount an effective immune response that favors COVID-19 recovery after drug discontinuation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Immunocompromised Host
/
Coronavirus Infections
/
Multiple Sclerosis, Relapsing-Remitting
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
/
Variants
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
J Neuroimmunol
Year:
2020
Document Type:
Article
Affiliation country:
J.jneuroim.2020.577282
Similar
MEDLINE
...
LILACS
LIS